BioSpace News Archive

The aggregate gross proceeds raised pursuant to the Offering is $8,572,500 through the issuance of 42,862,500 Units.

As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test. Therma Bright previously announced on November 4, 2020, that it would retain 50% of the revenue and profit from the sale of its rapid antigen test through Torion Biosciences Inc. (“Torion”).

Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise.

Vancouver, British Columbia--(Newsfile Corp. - January 25, 2021) - CVR Medical Corp. (TSXV: CVM) (OTC: CRRVF) (“CVR Medical” or the “Company” or “we”) a Canadian listed and US based healthcare company in the medical device market is pleased to share a message from new Chief Executive Officer (CEO) Michael Rhodes:

With less than a drop of blood, one of the lowest sample volumes on the market, the analyzer delivers high-quality results in 60 seconds or less

AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate

New Service Allows Patients the Convenience and Safety of Queuing up From Anywhere, Eliminating the Need to Wait in a Physical Line Outside of the Clinic

The pandemic has taken a toll on the mental and emotional well-being of physicians, with female physicians and those in critical care and infectious disease reporting among the highest rates during the pandemic, according to findings from Death by 1,000 Cuts: Medscape National Physician Burnout and Suicide Report 2021.

No adverse effects observed at all doses tested Using the results of this study, combined with previously compiled clinical safety data, the Company intends to commence evaluation of human equivalent doses for initiating pilot clinical efficacy studies An IND submission for Chemotherapy Induced Peripheral Neuropathy is expected in the second half of 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.